An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. Prednisone-induced insulin resistance may depend on either reduced sensitivity (receptor defect) or reduced response to insulin (postreceptor defect). To clarify the mechanism of prednisone-induced insulin resistance, a [3H]glucose infusion (1 microCi/min) was performed for 120 min before and during a euglycemic clamp repeated at approximately 100, approximately 1,000, and approximately 10,000 microU/ml steady state plasma insulin concentration in 10 healthy, normal weight subjects, aged 35 +/-7 yr. Each test was repeated after 7-d administration of placebo or prednisone (15 plus 15 mg/d per subject), in a randomized sequence with an interval of 1 mo between the two tests. Mean fasting blood glucose (89.5 +/-2.1 vs. 83.7 +/-1.9 mg/dl) and mean fasting plasma insulin values (17.8 +/-1.2 vs. 14.3 +/-0.8 microU/ml) were significantly higher (P less than 0.01) after prednisone. The insulin sensitivity index (glucose metabolic clearance rate in ml/kg per min) was significantly lower (P less than 0.001) after prednisone at all three steady state plasma insulin levels: 2.8 +/-0.3 vs. 7.4 +/-1.1 at approximately 100 microU/ml; 6.0 +/-0.5 vs. 12.2 +/-1.1 at approximately 1,000 microU/ml; 7.4 +/-0.6 vs. 14.4 +/-0.5 at approximately 10,000 microU/ml. Fasting glucose production (in mg/kg per min) was significantly higher after prednisone: 3.7 +/-0.2 vs. 2.9 +/-0.2, P less than 0.001. 0.14±0.13, NS), and total at -1,000 and -10,000 1uU/ ml after both prednisone and placebo. The metabolic kinetic parameters of insulin after prednisone were not significantly different from those after placebo. In addition, insulin binding and 3-ortho-methyl-glucose transport were studied in vitro on fat cells from 16 normal-weight surgical candidates aged 40±8 yr (10
A B S T R A C T Prednisone-induced insulin resistance may depend on either reduced sensitivity (receptor defect) or reduced response to insulin (postreceptor defect). To clarify the mechanism of prednisone-induced insulin resistance, a [3H]glucose infusion (1 ,uCi/ min) was performed for 120 min before and during a euglycemic clamp repeated at 100, -1,000, and -10,000 MU/ml steady state plasma insulin concentration in 10 healthy, normal weight subjects, aged 35±7 yr. Each test was repeated after 7-d administration of placebo or prednisone (15 plus 15 mg/d per subject), in a randomized sequence with an interval of 1 mo between the two tests. Mean fasting blood glucose (89.5±2.1 vs. 83.7± 1.9 mg/dl) and mean fasting plasma insulin values (17.8±1.2 vs. 14.3±0.8 AU/ml) were significantly higher (P < 0.01) after prednisone. The insulin sensitivity index (glucose metabolic clearance rate in ml/kg per min) was significantly lower (P < 0.001) after prednisone at all three steady state plasma insulin levels: 2.8±0.3 vs. 7.4±1.1 at '100 MU/ml; 6.0±0.5 vs. 12.2±1.1 at -1,000 psU/ml; 7.4±0.6 vs. 14.4±0.5 at -10,000 ,uU/ml. Fasting glucose production (in mg/ kg per min) was significantly higher after prednisone: 3.7±0.2 vs. 2.9±0.2, P < 0.001. Suppression of glucose production at steady state plasma insulin level of -100 IAU/ml was less after prednisone (1.01±0.35 vs. 0.14±0.13, NS), and total at -1,000 and -10,000 1uU/ ml after both prednisone and placebo. The metabolic kinetic parameters of insulin after prednisone were not significantly different from those after placebo. In addition, insulin binding and 3-ortho-methyl-glucose transport were studied in vitro on fat cells from 16 normal-weight surgical candidates aged 40±8 yr (10 Received for publication 9 February 1983 and in revised form 28 July 1983. treated with placebo and 6 with prednisone as above). No significant difference was observed with regard to specific insulin binding (tested with 1 ng/ml hormone only), whereas significant transport differences were noted at the basal level (0.40±0.10 vs. 0.54±0.12 pmol/ 105 cells, P < 0.05), and at increasing concentrations up to the maximum stimulation values (5 ng/ml): 0.59±0.04 vs. 0.92±0.12 pmol/105 cells, P < 0.005. These results suggest that (a) administration of an antiinflammatory dose of prednisone for 7 d induces insulin resistance in man; (b) this is more dependent on depressed peripheral glucose utilization than on increased endogenous production; (c) total insulin binding on isolated adipocytes is not significantly affected; (d) insulin resistance is primarily the outcome of postreceptor defect (impaired glucose transport).
INTRODUCTION
Like other glucocorticoids (1-4), prednisone increases blood glucose in man (5) . This effect is accompanied by hyperinsulinemia (insulin resistance) (6) that may be attributable to either reduced peripheral insulin sensitivity or increased hepatic glucose production (6) . Different glucocorticoids, too, may exert a different metabolic effect on the hepatic and peripheral sites (4) . It is not yet known whether this situation reflects reduced sensitivity (i.e., a receptor defect), a reduced response to insulin (i.e., a postreceptor defect), or both (7, 8) . Since an increase in insulin binding by glucocorticoids was reported in vitro study, a postreceptor mechanism must be taken in consideration. Account must also be taken of the fact that glucocorticoids bind to specific cytoplasmatic receptors and influence cell metabolism through a second messenger (9, 10) that also seems to act at the nuclear level. The result is a control of protein synthesis, maybe including modulation of receptor protein and glucose carriers turnover.
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The first postreceptor step, in fact, is that related to the transmembrane transport of glucose. This step can now be investigated in man (11).
In vivo use of the euglycemic clamp enables an assessment of insulin action in the periphery and a provisional discrimination between reduced response and/ or reduced sensitivity to the hormone (12) . Simultaneous examination of endogenous glucose production under basal conditions and during euglycemic-hyperinsulinemic clamp (13) (14) and infusion was continued for 2 h. Blood glucose was kept at ±5% of the fasting value by automatic infusion of a 30% dextrose solution through a Biostator (CGIIS, Ames, Elkhart, IN). Blood was withdrawn with a double-lumen Ames catheter in a wrist vein after arterialization by wrapping the hand in a thermophore at 60°C. Blood gas analyses in test studies on blood obtained in this manner had shown a Po2 of 88±3 mmHg. An adjacent cannula in the same vein was used in the evaluation of plasma glucose and insulin. The following constants were used in the formula: Dextrose infusion rate = RD QD + 1); where BD is blood glucose level at which basal dextrose infusion starts (equal to fasting blood glucose + 5%); QD is inverse of the static gain for dextrose infusion (equal to 45); RD is minimal amount of dextrose infused by Biostator (equal to 0.8 mg/kg X min [clamp at -100 ,uU/ml], 2 mg/kg X min [clamp at -1,000 IAU/ml], 3 mg/kg X min [clamp at -10,000 ,uU/ml]). The dextrose infusion tube was replaced by a Baxter hemotransfusing apparatus (flow = 5 ml/min). Potassium aspartate (15 and 25 meq/h, respectively) was infused during the clamp at steady state plasma insulin -1,000 and -10,000 MU/ml to prevent hypokalemia. Serum potassium values at the end of each clamp were not significantly different from the base lines.
Adipocytes were taken from the periumbilical subcutaneous tissue during the first few minutes of narcosis (nitrogen protoxide) (15) .
Analytical procedure. Glucose levels during the in vivo test automatically measured by the Biostator were also checked on plasma every 5 min with a Beckman II glucose analyzer. Good reproducibility was obtained (<5% variation). For calculation of all indexes, plasma glucose values were always used.
Specific plasma radioactivity during [3H]glucose infusion was determined according to Issekutz et al. (16) .
Plasma insulin was measured by solid-phase antibody radioimmunoassay (RIA) (Korning Kit, Medfield, MA). Separation of adipocytes by digestion with collagenase was performed as previously described (15) . Insulin binding to isolated adipocytes (106 cells) was performed in Krebs-Ringer bicarbonate buffer pH 7.4 (plus 1% bovine serum albumin) at 25°C in a 95:5% 02/CO2 atmosphere per 60 min in duplicate in the presence of 1 ng/ml monoiodoinsulin. Nonspecific binding was evaluated by subtracting radioactivity labeled to the cells in the presence of 100 ,ig native insulin. Adipocytes were separated and radioactivity was counted as previously reported (15) . Intracellular transport of glucose was performed according to Ciaraldi et al. (11) . Briefly, cells were preincubated for 60 min at 37°C in the presence of 0-5 ng/ml insulin. The substrate used, 3-ortho-methyl-['4C]glucose (3-OMG,l New England Nuclear, Boston, MA), enters the cell but is not metabolized. The reaction is blocked after 10 s with 0.3 mM cold phloretin, followed by centrifugation in silicone oil. The glucose space is corrected by a parallel study with L-['4C]glucose (Amersham).
Calculations. Endogenous glucose production (milligrams per killogram per minute) was determined from Steele's formula (17) . Fasting glucose production was calculated from the specific activity value (counts per minute per milliliter) of plasma glucose during the 110-120-min period of [3H]glucose infusion (steady state). Glucose production during the clamp was determined by subtracting the amount of dextrose infused from the isotopically determined total glucose production rate (endogenously produced plus exogenously infused). Negative glucose production values were treated as 0 (13, 18 al. (20) .
All values were expressed as means±SEM. The t test was used to compare the means obtained after placebo and prednisone.
RESULTS
Blood glucose and plasma insulin values after placebo and prednisone are shown in Table I . If fasting plasma glucose and insulin values are considered as a whole, it appears that prednisone was responsible for a significant (P < 0.01) increase in both plasma glucose (89.5±2.1 vs. 83.7±1.9 mg/dl) and insulin (17.8±1.2 vs. 14.3±0.8 ,uU/ml), whereas values during steady state plasma insulin were not significantly different after placebo and prednisone. Mean values of plasma glucose, plasma insulin, and dextrose infusion rate during euglycemic clamp at all three steady state plasma insulin levels are reported in Fig. 1 . M20-120 values were significantly lower (P < 0.001) after prednisone at steady state plasma insulin level: -100 jU/ml (2.5±0.2 vs. 6.1±0.5 mg/kg per min), l1,000,U/ml (4.9±0.2 vs. 11.1±0.6), and -10,000 AU/ml (7.2±0.2 vs.
13.4±0.4).
Glucose metabolic clearance rate (milliliter per kilogram per minute) was also significantly (P < 0.001) reduced after prednisone at all three steady state plasma insulin levels ( Fig. 2) : 2.8±0.3 vs. 7.4±1.1 at -100 ,uU/ml; 6.0±0.5 vs. 12.2±1.1 at -1,000 ,uU/ml; 7.4±0.6 vs. 14.4±0.5 at --10,000 ,uU/ml. Fasting glucose production was significantly increased after prednisone: 3.7±0.2 vs. 2.9±0.2 mg/kg per min (P < 0.01) (Fig.  3) . Suppression of glucose production was never complete during steady state plasma insulin level of -100
,uU/ml after prednisone (1.01±0.35 vs. 0.14±0.13 mg/ kg per min, NS), whereas total suppression after both placebo and prednisone was observed at steady state plasma insulin levels of --1,000 and --10,000 ,uU/ml. The increase in insulin basal systemic delivery rate after prednisone was not significant: 0.23±0.02 vs. 0.19±0.01 mU/kg per min. The change in insulin metabolic clearance rate after prednisone was not significant: 14.3±0.7 vs. 13.9±0.7 ml/kg per min at -100 ,uU/ml; 10.1±0.7 vs. 12.1±0.8 at -1,000 AU/ml and 3.6±0.2 vs. 3.7±0.3 at -10,000 ,uU/ml. Specific insulin binding was determined at only one level of insulin concentration, owing to the difficulty of obtaining enough fat for the study of the glucose transport and the competition curve. It was much the same after prednisone and placebo (4.45 vs. 4.48%) (Fig. 4) . Glucose transport is illustrated in Fig. 5 . There is a significant decrease after prednisone not only at the base line (absence of insulin) (0.40±0.10 vs. 0.54±0.12 pmol/ 105 cells, P < 0.05), but also at increasing insulin concentrations (Fig. 5 A) . The kinetics of glucose transport is significantly different up to the maximum insulin stimulation of transport (5 ng/ml): 0.59±0.04 vs. 0.92±0.12 pmol/105 cells, P < 0.005. The percentage of the maximal response was much the same after placebo and prednisone (Fig. 5 B) , whereas the percent increase over basal transport was lower after prednisone at insulin concentrations of 0.5 ng/ml (Fig. 5 C) . DISCUSSION These results suggest that an average antiinflammatory dose of prednisone administered for 7 d induces insulin resistance characterized by depressed peripheral uti- of the dose-response curve). According to Kahn's model (7) , therefore, it can be supposed that the defect is both receptor and postreceptor as also suggested by Rizza et al. (6) . Fasting glucose production in our study ap- 
( n= 6 ) ( P=6 FIGURE 3 Glucose production (milligrams per killogram X minute). Endogenous glucose production assessed by
[3H]glucose infusion (17) and calculated during fasting (-10 uU/ml plasma insulin concentration) and hyperinsulinemic steady state (-100, -1,000, and -10,000 MU/ml) after pla- (8, 21) , a decrease (22) , or no change (23) in the number of insulin receptors, or a change in receptor affinity (24) 
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Pagano et al. Yasuda and Kitabchi (27) cannot be ruled out. In addition, insulin sensitivity of 3-OMG transport in fat cells was much the same after both placebo and prednisone (Fig.  5 B) . Glucose transport is significantly reduced in the basal state as well as in the presence of insulin up to 5 ng/ml (maximum effective concentration of insulin added in vitro) (Fig. 5, A and C) . This is clear evidence of postreceptor defect, in line with our data in vivo and the deduction of Rizza et al. (6) . The existence of a 3-OMG transport defect could be ascribed to the nonavailability of the specific carrier described by Czech (28) . According to other workers (29, 30) , energyand hormone-dependent translocation of the carrier systems takes place from a pool of intracellular membranes to the plasma membrane.
Since steroids, after binding to cytoplasmic receptors, signal the nucleus (9) and modify cellular enzyme activities (10), they may have either a direct or indirect effect on the glucose transport system. Evidence in favor of a direct effect can be seen in the results of Olefsky's study (31) ; dexamethasone action in rat adipocytes is not due to nonspecific binding to the plasma membrane but to specific reaction with an intracellular receptor. The possibility of an indirect effect, however, cannot be entirely ruled out. This could be due, for example, to the decrease in contrainsular hormones postulated by some workers (32) 
